Circulating Biomarkers Predictive of Treatment Response in Patients with Hormone-sensitive or Castration-resistant Metastatic Prostate Cancer: A Systematic Review

This publication has 89 references indexed in Scilit:

• Plasma progastrin‐releasing peptide level shows different predictive profiles for treatment response by androgen receptor axis‐targeted agents in patients with metastatic castration‐resistant prostate cancer
  Cancer Reports, 2022
• Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing Interference
  JAMA Oncology, 2021
• Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in TP53 Wild-Type Metastatic Castration-Resistant Prostate Cancer
  JAMA Oncology, 2019
• Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer
  JAMA Oncology, 2018
• Patient-Paired Sample Congruence Between 2 Commercial Liquid Biopsy Tests
  JAMA Oncology, 2018
• Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide
  International Journal of Cancer, 2018
• Comparison of 2 Commercially Available Next-Generation Sequencing Platforms in Oncology
  JAMA Oncology, 2017
• Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer
  JAMA Oncology, 2016
• Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer
  JAMA Oncology, 2016
• Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
  JAMA Oncology, 2015